Your browser doesn't support javascript.
loading
Prosigna test in breast cancer: real-life experience.
Hequet, D; Harrissart, G; Krief, D; Maumy, L; Lerebours, F; Menet, E; Callens, C; Rouzier, R.
Afiliación
  • Hequet D; Department of Surgical Oncology, Institut Curie, St Cloud, France. Delphine.hequet@curie.fr.
  • Harrissart G; INSERM U900, Institut Curie, St Cloud, France. Delphine.hequet@curie.fr.
  • Krief D; Department of Surgical Oncology, Institut Curie, St Cloud, France.
  • Maumy L; Department of Surgical Oncology, Institut Curie, St Cloud, France.
  • Lerebours F; Department of Surgical Oncology, Institut Curie, St Cloud, France.
  • Menet E; Department of Medical Oncology, Institut Curie, St Cloud, France.
  • Callens C; Department of Pathology, Institut Curie, St Cloud, France.
  • Rouzier R; Pharmacogenomics Unit, Department of Genetics, Institut Curie, Paris, France.
Breast Cancer Res Treat ; 188(1): 141-147, 2021 Jul.
Article en En | MEDLINE | ID: mdl-33860387
PURPOSE: Genomic tests can guide the decision to administer adjuvant chemotherapy in women with hormone receptor (HR)-positive, Human Epidermal growth Factor 2 (HER2)-negative breast cancer (BC) at intermediate risk of recurrence. We assessed the decision-making and economic impact of the Prosigna test in a real-life setting. METHODS: Retrospective cohort study of HR + , HER2- BC patients managed from 2016 to 2020, potential candidates for adjuvant chemotherapy, at intermediate risk of recurrence, in whom a Prosigna test was performed according to contemporary guidelines. The additional cost of chemotherapy over one year in terms of direct medical and non-medical costs was estimated in this study to be €9,737 (derived from a previous study, NCT02813317). The cost of the Prosigna test, as defined by the reimbursement system, was €1,849. RESULTS: Among the 809 patients included in this study, 2.3 Prosigna tests had to be performed to avoid adjuvant chemotherapy for one patient. The number of tests that had to be performed to avoid chemotherapy for one patient was higher for patients with grade 3 tumors and pN1mic axillary node involvement and lower for grade 1 tumors or in the absence of axillary node involvement (pN0), but did not vary according to the 10-year overall survival gain predicted by the Predict online test. The cost saving related to withholding of adjuvant chemotherapy for one patient on the basis of the Prosigna test results was €5,485. CONCLUSION: We present one of the largest cohorts of HR + , HER2- BC patients at intermediate risk of recurrence, in whom a Prosigna test was used to guide the adjuvant therapy decision in a real-life setting, resulting in a 44% decrease in the indication for chemotherapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Toma de Decisiones Clínicas Tipo de estudio: Guideline / Health_economic_evaluation / Observational_studies / Prognostic_studies Límite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Toma de Decisiones Clínicas Tipo de estudio: Guideline / Health_economic_evaluation / Observational_studies / Prognostic_studies Límite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Países Bajos